The first person with chronic obstructive pulmonary disease (COPD) has now been dosed with BBT002, an experimental medication being developed by Bambusa Therapeutics, in an ongoing Phase 1b clinical trial. The trial (NCT06944925) is evaluating BBT002’s safety and pharmacological properties against a placebo in up to 98…